The strength of our investigation is our relatively homogenous pt population: all patients had stage IV adenocarcinoma, the percentage of KRAS MT is similar to that reported in the literature, all patients received platinum based doublet chemotherapy in 1st line and a majority of patients received a contemporary regimen of carboplatin and pemetrexed. Here, KRAS is linked to adenocarcinoma.